Jakafi (ruxolitinib) - Incyte
Successful Management of Severe Hepatic Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β-Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation. (PubMed, Clin Case Rep) - Sep 28, 2026 - "Severe hepatic acute graft-versus-host disease can occur early after allogeneic hematopoietic stem cell transplantation without skin involvement, presenting with rapidly progressive cholestatic liver dysfunction. Early recognition and prompt escalation to multimodal immunosuppressive therapy achieve complete biochemical remission and durable hematopoietic recovery, highlighting the crucial role of early, multidisciplinary pediatric management." 
Journal • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hepatology • Immunology • Liver Failure • Pediatrics • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42801017
 
Amal Ali Fares; Hind Alhiraki; Maged Kheder
 
Sep 28, 2026
 
Prev Next